<DOC>
	<DOCNO>NCT01939977</DOCNO>
	<brief_summary>To demonstrate superiority paricalcitol treatment early renal post-transplantation ( M6 ) control iPTH ( Intact parathyroid hormone ) compare use vitamin D nutritional supplement ( calcifediol ) patient renal transplantation .</brief_summary>
	<brief_title>Efficacy Safety Paricalcitol Reduction Secondary Hyperparathyroidism After Kidney Transplantation .</brief_title>
	<detailed_description>The purpose study demonstrate superiority paricalcitol treatment early renal post-transplantation ( M6 ) control iPTH ( Intact parathyroid hormone ) compare use vitamin D nutritional supplement ( calcifediol ) patient renal transplantation .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcifediol</mesh_term>
	<criteria>Patient willingly sign date ICD ( Informed Consent Document ) approve EC ( Ethics Committee ) study procedure explain study , read ICD opportunity make question . Patients gender older 18 year candidate immediately renal transplantation living decease donor . 24 hour previous transplantation , patient must significant grade secondary hyperparathyroidism , define iPTH level 110 600 pg/mL per central laboratory result . Patients preform antibody panel &lt; 20 % 24 hour transplantation consider investigator low immunological risk ( PRA determination do local laboratory , central ) . Serum calcium ( correct albumin ) &lt; 10 mg/dL 24 hour previous transplantation per central laboratory result . Patients treat immunosuppression base tacrolimus , mofetil mycofenolate mycophenolic acid steroid go treated mTOR ( mammalian target rapamycin ) inhibitor . Tacrolimus steroid must remove 6 month posttransplantation . Patients able take oral capsule first week posttransplantation . Third subsequent renal transplantation . Positive crossmatch assay ABO ( AB0 ) incompatibility Patients go recipient organs kidney double kidney transplantation . Patients history allergic reaction sensibility paricalcitol , calcifediol similar study drug ( relate vitamin D ) . Patients chronic gastrointestinal disease , , base investigator criterion , cause significant gastrointestinal malabsorption . Patient hypo hyperthyroidism control base investigator criterion . Patient uncontrolled hypertension base investigator criterion . Patients , 48 hour previous transplantation , receive calcimimetics . Patients VIH ( human immunodeficiency virus ) infection positive serology HBV ( hepatitis B virus ) and/or HCV ( hepatitis C virus ) Patients treatment drug contraindicate paricalcitol calcifediol ( base SMPC ) Patients participate clinical trial investigational drug . Women childbearing potential ( define whose last menstruation &lt; 2 year ago surgically sterilize ) willing use correct contraception study treatment . Patient disease condition base investigator criterion suitable study . Treatment start CalciumPhosphorus product ( CAxP ) &gt; 55 mg2/dL2 case hyperphosphatemia consider significant per investigator criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hyperparathyroidism</keyword>
	<keyword>Hyperparathyroidism Secondary</keyword>
	<keyword>Paricalcitol</keyword>
	<keyword>Calcifediol</keyword>
	<keyword>Parathyroid hormone</keyword>
	<keyword>Renal transplantation</keyword>
</DOC>